Your Search for 'Reimbursement in Europe, Japan and the US: The Impact of Cost Shifting on Pharmaceutical Strategies' returned 23 results - Page 1 of 2
Decision Resources, Inc., May 2010, Pages: 37
and implications for the pharmaceutical industry: challenges to the implementation of U.S. healthcare reform and impact on drug manufacturers; future emphasis of French government’s cost-containment strategy
Decision Resources, Inc., Oct 2009, Pages: 40
drug use; proposed prescribing and reimbursement restrictions; shifting patterns of parallel trade; impact of the economic downturn on the pharmaceutical market; access to medicines.
- Issues affecting
Business Insights, Nov 2007, Pages: 143
for drugs/services in Japan
-Classification for price premium (Japanese healthcare system)
-Future pricing scenarios in JapanPharmaceutical Pricing and Reimbursement: Strategies for Market Access Across
PharmaVentures, July 2007, Pages: 88
One market one launch strategy?
The outlook for Europe
Pricing and reimbursement in Japan
Controlling Japan’s healthcare costs
Getting onto the NHI list
Changes to reward innovation
Generic Drug
PharmaVision, Aug 2010, Pages: 183
and the reproducibility of complex proteins, which is central to discovery and characterisation of new TPs.
- Regulatory agencies from the US, Europe, and Japan are making efforts to collaborate and coordinate
Datamonitor, July 2010, Pages: 195
generic usage, Italy employs a range of pricing and reimbursement tools to control costs. As a result, drug prices in Italy are among the lowest in Europe, a factor which is largely behind the country
Ovum, Nov 2010, Pages: 29
sales and rising R&D costs, the industry is expanding out of the developed markets of US, Europe and Japan, into the emerging markets, particularly China and India. Experiencing tremendous growth already
TriMark Publications, Nov 2011, Pages: 189
Testing
12.9 European Reimbursement Practices
12.10 Cost Containment in Europe
12.11 Significant Factors that Provide Competitive Advantage
12.12 Sales and Marketing Strategies for POCT
12.12.1 North
Markets and Markets, Feb 2011, Pages: 264
.27.1 Overview
17.27.2 Products & Services
17.27.3 Strategy
17.27.4 Develop0Ments
U.S. Patents
Europe Patents
Japan Patents
List Of Tables
1 Top 10 Drug Delivery Technologies Market, By Segments 2008 – 2015
Decision Resources, Inc., June 2006, Pages: 28
and Personalized Medicine
EuropeJapan
- Outlook
The Public’s Perspective
Pricing and Reimbursement
Development of Diagnostic Tests
List of Figures & Tables
Figure 1 Application of Pharmacogenomics and Effects
Burrill & Company, April 2011, Pages: 370
of External Products Will Grow
2.6 Divergent Rates of Growth of Pharmaceutical Markets
2.7 Pharma Innovation Gap
2.8 Drug Development Cost Estimate Curve
2.9 A Changed Environment: Substantially Reduced
Markets and Markets, Jan 2010, Pages: 300
, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies - US, Europe, APAC, ROW.
- 15 pages of high level analysis including benchmarking strategies
GlobalData, Nov 2010, Pages: 357
.7.4 Forecasts
3.7.5 Drug Sales
3.7.6 Pricing and Reimbursements
3.8 Japan
3.8.1 Market Size
3.8.2 Drivers and Barriers
3.8.3 Impact on the Market
3.8.4 Forecasts
3.8.5 Future Impact
3.8.6
3.8.7 Drug
GlobalData, Nov 2010, Pages: 436
Sales
3.7.6 Pricing and Reimbursements
3.8 Japan
3.8.1 Market Size
3.8.2 Drivers and Barriers
3.8.3 Impact on the Market
3.8.4 Forecasts
3.8.5 Future Impact
3.8.6 Drug Sales
3.8.7 Pricing
TriMark Publications, May 2011, Pages: 2116
issues that impact the use of cardiac rhythm devices are explored for countries like the U.S., Japan, Australian, Korea, India, China, Israel, the Philippines, and those in the E.U. Reimbursement
Synergyst, Jan 2012, Pages: 80
. KEY GENERIC DRUGS MARKETS AND REGULATIONS
a. United States
i. Market Sizing and Forecast
ii. U.S. Regulations
b. Japan
i. Market Sizing and Forecast
ii. Japanese Regulations
c. Europe
i. Market Sizing
GlobalData, April 2011, Pages: 308
and Barriers
3.7.3 Impact on the Market
3.7.4 Forecasts
3.7.5 Drug Sales
3.7.6 Pricing and Reimbursements
3.8 Japan
3.8.1 Market Size
3.8.2 Drivers and Barriers
3.8.3 Impact on the Market
3
Markets and Markets, Nov 2010, Pages: 316
dental procedures
3.7 Limited reimbursement & high cost are detrimental
3.8 Radiology aids in quick diagnosis
3.9 Future growth in developing countries
3.9.1 North America
3.9.2 Europe
3.9.3 Asia
3
